@entity3494 has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of @entity281 . In the early 1990s, reports from China described impressive results with @entity4447 in @entity1 with de novo, relapsed, and refractory @entity2799 ( @entity2799 ). Other investigators subsequently confirmed these results leading to approval of its use for relapsed or refractory @entity2799 in the United States. Investigations of this agent have demonstrated that its efficacy in @entity2799 and preclinical @entity5 models is dependent upon a number of mechanisms, including induction of apoptosis, effects on cellular differentiation, cell cycling, and @entity5 angiogenesis. Subsequent preclinical studies showed significant activity of @entity4447 in @entity1582 ( @entity1582 ). Based on this, in a phase II trial, we have evaluated the activity of @entity4447 in 14 @entity1 with relapsed @entity1582 , refractory to conventional salvage therapy. With the dose and schedule used, treatment with @entity4447 produced responses in three @entity1 and prolonged stable disease in a fourth @entity1 , with the longest response lasting 6 weeks. Although treatment was reasonably well tolerated, in these @entity1 with extensive prior therapy, 11 developed @entity1503 , five associated with infectious complications and three developed @entity1150 . The results of this small trial support further investigation of this novel drug for the treatment of @entity1 with relapsed or refractory @entity1582 .

Clinical activity of XXXX for the treatment of @entity1582 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4447 :: ('MESH:C006632', 'Chemical') :: ['arsenic trioxide'] @entity2799 :: ('MESH:D015473', 'Disease') :: ['APL', 'acute promyelocytic leukemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM'] @entity281 :: ('MESH:D007239', 'Disease') :: ['parasitic infections'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['cytopenia'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thromboses'] @entity3494 :: ('MESH:D001151', 'Chemical') :: ['Arsenic']
@entity4447 :: (MESH:C006632,Chemical) :: ['arsenic trioxide']
